MedTrace Logo

Colorectal Cancer Screening French Organizations for the Follow-up After Colonoscopy

NCT03383367 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33000

Last updated 2017-12-26

No results posted yet for this study

Summary

France is one of the European countries where the incidence of colorectal cancer is the highest among cancers for both sexes. Fecal occult blood screening has been implemented since 2008. However, this screening excludes high risk people who have a 10 to 30 % risk of developing a CRC during their lifetime. Colonoscopy follow up of these persons is not organized, and it is up to the attending physician to recall the date of the surveillance colonoscopy. This results in a poor compliance with the recommendations by these people. A postal reminder of the surveillance colonoscopies sent by The French screening organizations to the patients should increase adherence to follow-up recommendations. The colorectal cancer screening organizations will collects from the hepatogastroenterologists (HGE) informations on colonoscopies of people more than 50 years old who live in the Rhone. These informations will allow to send a reminder 3 months before the date recommended by the HGE. Participation rate and timeliness will be assessed, as well as the severity of the lesions found. A medico-economic analysis will also be carried out.

Conditions

Interventions

BEHAVIORAL

Tempo Colo

Reminder letter for people at high risk of colorectal cancer.

Sponsors & Collaborators

  • National Cancer Institute, France

    collaborator OTHER_GOV

  • Association pour le Dépistage Organisé des Cancers dans le Rhône

    lead OTHER

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-24
Primary Completion
2018-11-30
Completion
2018-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03383367 on ClinicalTrials.gov